Alpha DaRT
Skin Cancer (including Skin Metastases, Recurrent Cancer)
Key Facts
About Alpha Tau Medical
Alpha Tau Medical is developing a breakthrough alpha-radiation therapy for solid tumors, with its core Alpha DaRT technology originating from Tel Aviv University in 2003. The company is now in clinical execution mode, with multiple active, recruiting trials across seven cancer types at leading global cancer centers. Its strategic focus is on demonstrating efficacy and safety across a diverse oncology portfolio to address significant unmet needs in both accessible and hard-to-treat tumors.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical is developing a breakthrough alpha-radiation therapy for solid tumors, with its core Alpha DaRT technology originating from Tel Aviv University in 2003. The company is now in clinical execution mode, with multiple active, recruiting trials across seven cancer types at leading global cancer centers. Its strategic focus is on demonstrating efficacy and safety across a diverse oncology portfolio to address significant unmet needs in both accessible and hard-to-treat tumors.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical is developing a breakthrough alpha-radiation therapy for solid tumors, with its core Alpha DaRT technology originating from Tel Aviv University in 2003. The company is now in clinical execution mode, with multiple active, recruiting trials across seven cancer types at leading global cancer centers. Its strategic focus is on demonstrating efficacy and safety across a diverse oncology portfolio to address significant unmet needs in both accessible and hard-to-treat tumors.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical is developing a breakthrough alpha-radiation therapy for solid tumors, with its core Alpha DaRT technology originating from Tel Aviv University in 2003. The company is now in clinical execution mode, with multiple active, recruiting trials across seven cancer types at leading global cancer centers. Its strategic focus is on demonstrating efficacy and safety across a diverse oncology portfolio to address significant unmet needs in both accessible and hard-to-treat tumors.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical is developing a breakthrough alpha-radiation therapy for solid tumors, with its core Alpha DaRT technology originating from Tel Aviv University in 2003. The company is now in clinical execution mode, with multiple active, recruiting trials across seven cancer types at leading global cancer centers. Its strategic focus is on demonstrating efficacy and safety across a diverse oncology portfolio to address significant unmet needs in both accessible and hard-to-treat tumors.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical is developing a breakthrough alpha-radiation therapy for solid tumors, with its core Alpha DaRT technology originating from Tel Aviv University in 2003. The company is now in clinical execution mode, with multiple active, recruiting trials across seven cancer types at leading global cancer centers. Its strategic focus is on demonstrating efficacy and safety across a diverse oncology portfolio to address significant unmet needs in both accessible and hard-to-treat tumors.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical is developing a breakthrough alpha-radiation therapy for solid tumors, with its core Alpha DaRT technology originating from Tel Aviv University in 2003. The company is now in clinical execution mode, with multiple active, recruiting trials across seven cancer types at leading global cancer centers. Its strategic focus is on demonstrating efficacy and safety across a diverse oncology portfolio to address significant unmet needs in both accessible and hard-to-treat tumors.
View full company profile